Mizuho Raises Humana (HUM) Price Target to $495

Mizuho has reiterated its Outperform rating on Humana Inc. (NYSE: HUM) on October 13, 2026, with a new price target of $495, up from a previous target of $468. The stock was recently trading at $418.36, which places it about 15.5% below this target.

Mizuho's Call on Humana

Mizuho's updated target reflects its positive outlook on Humana's performance in the healthcare sector. The firm believes that the company's strong fundamentals justify the higher target.

Other Institutional Activity in Humana

Several other institutional investors have recently adjusted their positions in Humana. Dodge & Cox Inc. reduced its stake by 440,438 shares, ending with 10,940,380 shares valued at about $4.5 billion. Blackrock Inc. increased its holdings slightly by 218,270 shares, bringing its total to 10,417,803 shares worth around $4.3 billion. Vanguard Capital Management LLC added 4,703 shares, resulting in a total of 7,843,620 shares valued at approximately $3.2 billion.

Humana Inc. Stock Down 2.1%

Humana's shares are currently trading above both their 50-day moving average by 6.5% and their 200-day moving average by 39.3%. However, they remain below their 52-week high of $456.50 by about 8.4%. This performance indicates a strong position relative to longer-term averages, but the stock still has room to grow to reach its analysts' targets.

Recent Earnings

For the trailing twelve months, Humana reported a revenue of approximately $145.7 billion and an EPS of $10.88. The company has shown a revenue growth of 26.2% year-over-year, signaling strong demand for its healthcare services. The next earnings report is scheduled for November 6, 2026.

Insider Buying and Selling at Humana Inc.

On February 23, 2026, Sanjay K Shetty, an officer at Humana, bought 810 shares at an average price of $185.20, totaling about $150,016. This purchase reflects confidence in the company's future prospects.

Analysts Set New Price Targets

On October 12, 2026, UBS maintained a Neutral rating on Humana with a price target of $495, up from $405. Truist Securities also maintained a Hold rating but increased its target to $475 from $415. Oppenheimer maintained its Outperform rating, raising its target to $525 from $475. Raymond James upgraded its rating to Outperform with a target of $520, indicating a positive outlook on the stock.

About Humana

Humana Inc. offers medical and specialty insurance products across the United States, operating mainly in the Insurance and CenterWell segments. The company's strong market presence and diverse product offerings position it well for future growth, especially as the healthcare industry evolves.

Bottom Line

Investors will be watching Humana closely as it approaches its next earnings date on November 6, 2026. Mizuho's updated target highlights the potential upside for the stock, which remains below analyst expectations. Further updates from other analysts and institutional investors could provide additional insights into Humana's market performance.